Because an erastin analog has not yet been tested in clinical trials, the use of tolerable drugs that inhibit SOD2 may promote ferroptosis while eliminating TMZ resistance in mesenchymal GBM; however, future studies on this topic are warranted. This evidence concerns the gene SOD2 and glioblastoma.